PLU Ophthalmic

PLU Ophthalmic is a US-based medical device company developing next-generation glaucoma surgical technology. The company focuses on advanced glaucoma care solutions that bridge the current clinical gap between traditional high-efficacy but high-risk procedures (trabeculectomy) and minimally invasive glaucoma surgery (MIGS) techniques that offer superior safety but limited efficacy. PLU Ophthalmic's proprietary technology employs precise micro-excision methodology to deliver implant-free glaucoma surgery with superior intraocular pressure reduction, enhanced safety profile, and minimal learning curve compared to existing MIGS platforms. The technology addresses a significant clinical need: glaucoma is the second leading cause of blindness globally, affecting approximately 80,000 people worldwide with 3 million cases in the US and a projected economic burden of $12 billion by 2032 and $17.3 billion by 2050. The company's solution targets ophthalmologists and glaucoma specialists seeking to improve surgical efficacy while reducing procedural risk and post-operative complications. PLU Ophthalmic emphasizes simplified patient management, enhanced patient outcomes, and improved OR productivity through shorter surgical times and reduced post-operative care requirements. The platform is designed to outperform current MIGS offerings while maintaining a safety advantage over traditional trabeculectomy, positioning it as a transformative approach in glaucoma surgical care.